The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Eli Lilly and Co's Revenue for the
three
months ended in Mar. 2026 was €17,126 Mil. Eli Lilly and Co's average Accounts Receivable for the
three
months ended in Mar. 2026 was €15,554 Mil.
Hence, Eli Lilly and Co's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.10.
Eli Lilly and Co (HAM:LLY) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Eli Lilly and Co Receivables Turnover Related Terms
Eli Lilly and Co Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Eli Lilly and Co's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:LLY vs JNJ, ABBV, MRK: Receivables Turnover Comparison
For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eli Lilly and Co Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Eli Lilly and Co's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eli Lilly and Co (HAM:LLY) has a Receivables Turnover of 1.10 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Eli Lilly and Co and its competitors. According to the industry distribution chart, Eli Lilly and Co ranks #536 out of 950 companies in the Drug Manufacturers industry, placing it in the top 56.4%.
Is Eli Lilly and Co's Receivables Turnover too high?
Eli Lilly and Co's current Receivables Turnover is 1.10. The Drug Manufacturers industry median Receivables Turnover is 5.07. Eli Lilly and Co's value of 1.10 is 78.3% below this industry median. Based on the distribution chart, Eli Lilly and Co ranks #536 out of 950 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Eli Lilly and Co has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's Receivables Turnover compare to JNJ and ABBV?
According to the Drug Manufacturers industry distribution chart, Eli Lilly and Co ranks #536 out of 950 companies for Receivables Turnover. This places Eli Lilly and Co in the lower half of its industry. The industry median Receivables Turnover is 5.07. Eli Lilly and Co's value of 1.10 is 78.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eli Lilly and Co's current Receivables Turnover of 1.10 is 78.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Eli Lilly and Co and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eli Lilly and Co's current Receivables Turnover is 1.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (HAM:LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is €1,243.42, compared to a current price of €1,038.00 — trading 16.5% below its estimated fair value. The current Receivables Turnover is 1.10 and 78.3% below the Drug Manufacturers industry median of 5.07. Eli Lilly and Co's overall GF Score™ is 96/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Eli Lilly and Co (HAM:LLY), the current Receivables Turnover is 1.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eli Lilly and Co (HAM:LLY) Overvalued in 2026?
Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued.
The current stock price of €1,038.00 is trading 16.5% below its estimated GF Value™ of €1,243.42.
GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.
Key valuation signals for HAM:LLY:
Receivables Turnover: 1.10
GF Value™: €1,243.42 vs. price of €1,038.00 (16.5% below fair value)
Industry Position: 78.3% below the Drug Manufacturers median (#536 of 950)
No single metric tells the full story. See the HAM:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
96GF Score
Get the complete analysis for HAM:LLY
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:LLY has been successfully added to your 
